{"id":43040,"date":"2024-10-21T15:38:51","date_gmt":"2024-10-21T13:38:51","guid":{"rendered":"https:\/\/www.maiwald.eu\/publikationen\/eu-pharmaceutical-reforms-propose-changes-to-regulatory-protection-periods-managing-ip-2024\/"},"modified":"2024-11-28T08:58:07","modified_gmt":"2024-11-28T07:58:07","slug":"eu-pharmaceutical-reforms-propose-changes-to-regulatory-protection-periods-managing-ip-2024","status":"publish","type":"publikationen","link":"https:\/\/www.maiwald.eu\/de\/publikationen\/eu-pharmaceutical-reforms-propose-changes-to-regulatory-protection-periods-managing-ip-2024\/","title":{"rendered":"EU pharmaceutical reforms propose changes to regulatory protection periods, Managing IP 2024"},"content":{"rendered":"\n<p>Dr. Christian Meyer und Dr. Gisela Grabow er\u00f6rtern m\u00f6gliche \u00c4nderungen der EU-Arzneimittelverordnung und deren potentielle Auswirkungen auf die Fristen f\u00fcr den Daten- und Marktschutz von Arzneimitteln.<\/p>\n\n\n\n<p><\/p>\n","protected":false},"template":"","meta":{"_acf_changed":false,"footnotes":""},"class_list":["post-43040","publikationen","type-publikationen","status-publish","hentry"],"acf":[],"_links":{"self":[{"href":"https:\/\/www.maiwald.eu\/de\/wp-json\/wp\/v2\/publikationen\/43040","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.maiwald.eu\/de\/wp-json\/wp\/v2\/publikationen"}],"about":[{"href":"https:\/\/www.maiwald.eu\/de\/wp-json\/wp\/v2\/types\/publikationen"}],"version-history":[{"count":3,"href":"https:\/\/www.maiwald.eu\/de\/wp-json\/wp\/v2\/publikationen\/43040\/revisions"}],"predecessor-version":[{"id":43732,"href":"https:\/\/www.maiwald.eu\/de\/wp-json\/wp\/v2\/publikationen\/43040\/revisions\/43732"}],"wp:attachment":[{"href":"https:\/\/www.maiwald.eu\/de\/wp-json\/wp\/v2\/media?parent=43040"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}